United States:
FDA Requests Comments On PDUFA Patient-Focused Development
27 October 2014
Jones Day
To print this article, all you need is to be registered or login on Mondaq.com.
In the October 8, 2014, Federal Register, FDA called for comments on
its preliminary list of disease areas for study under FDA's
patient-focused drug development initiative under the Prescription
Drug User Fee Act ("PDUFA"). Comments due December 5,
2014.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Food, Drugs, Healthcare, Life Sciences from United States
FDA Ramps Up Actions On PFAS
Holland & Knight
The U.S. Food and Drug Administration (FDA) has increased regulatory activity with regard to per- and polyfluoroalkyl substances (PFAS).
